Dr. Raje on the Utilization of bb21217 in Relapsed/ Refractory Multiple Myeloma

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

In the phase 1 CRB-402 trial (NCT03274219), investigators studied the use of bb21217, a BCMA-targeted CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

Updated findings from the trial showed that the overall response rate (ORR) was approximately 80%, and rates were similar among patients who received prior treatment with a PI3K inhibitor, Raje adds. At the highest dose of bb21217 of 450 × 106 CAR+ T cells explored during the dose-exploration trial, the ORR was more than 80%, Raje explains. 

Regarding toxicity, no new safety signals were seen, though central nervous system toxicity was observed at grades 1 and 2, Raje continues. These toxicity findings were similar to findings reported with the use of idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel; Carvykti), Raje concludes.